Eton Pharma Stock Is Trading Higher After FDA Approval For Rezipres

The FDA has approved Eton Pharmaceuticals Inc's ETON Rezipres (ephedrine hydrochloride injection) to treat clinically significant hypotension occurring in the setting of anesthesia.
Rezipres is already available in Europe.
The company currently owns or receives royalties from four FDA-approved products, including Alkindi Sprinkle, Biorphen, Rezipres, and Alaway Preservative Free, and has five additional products that have been submitted to the FDA.
Price Action: ETON shares are up 7.06% at $6.98 during the market session on the last check Tuesday.

Momentum98.03

Growth15.93

QualityNot Available

Value18.95

Short

Medium

Long